Janux Therapeutics, Inc. (JANX)

NASDAQ: JANX · Real-Time Price · USD

16.12

+0.12 (0.75%)

At close: Aug 14, 2026, 4:00 PM EDT

15.80

-0.32 (-1.99%)

After-hours: Aug 14, 2026, 7:56 PM EDT

Janux Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	24	10	10.59	8.08	8.61	3.64
Revenue Growth	5366.97%	-5.55%	30.99%	-6.14%	136.79%	-
Cost of Revenue	123.98	125.9	68.39	54.92	53.44	26.24
Gross Profit	-99.98	-115.9	-57.8	-46.84	-44.83	-22.6
Selling, General & Admin	43.57	41.77	41.05	26.14	22.26	10.33
Operating Expenses	43.57	41.77	41.05	26.14	22.26	10.33
Operating Income	-143.56	-157.67	-98.85	-72.98	-67.09	-32.93
Interest & Investment Income	40.96	44.04	29.85	14.69	4.03	0.26
EBT Excluding Unusual Items	-102.59	-113.63	-68.99	-58.29	-63.06	-32.67
Pretax Income	-102.59	-113.63	-68.99	-58.29	-63.06	-32.67
Net Income	-102.59	-113.63	-68.99	-58.29	-63.06	-32.67
Net Income to Common	-102.59	-113.63	-68.99	-58.29	-63.06	-32.67
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	62	62	54	44	41	24
Shares Outstanding (Diluted)	62	62	54	44	41	24
Shares Change	6.20%	15.28%	22.12%	6.14%	76.24%	2471.20%
EPS (Basic)	-1.64	-1.83	-1.28	-1.32	-1.52	-1.39
EPS (Diluted)	-1.64	-1.83	-1.28	-1.32	-1.52	-1.39
EPS Growth	-	-	-	-	-	-
Free Cash Flow	-41.93	-83.28	-44.17	-52.43	-49.37	-18.46
Free Cash Flow Per Share	-0.67	-1.34	-0.82	-1.19	-1.19	-0.78
Operating Margin	-598.15%	-1576.67%	-933.58%	-902.87%	-779.04%	-905.39%
Profit Margin	-427.47%	-1136.25%	-651.62%	-721.18%	-732.22%	-898.32%
Free Cash Flow Margin	-174.69%	-832.78%	-417.20%	-648.58%	-573.24%	-507.51%
EBITDA	-141.65	-155.64	-96.79	-71.02	-66.25	-32.82
D&A For EBITDA	1.9	2.03	2.06	1.96	0.84	0.11
EBIT	-143.56	-157.67	-98.85	-72.98	-67.09	-32.93

SEC Filings: 10-K · 10-Q